Changing lives through
innovation
SNAPSHOT
Building a track record of success
+
active product programs
M+
invested in innovation & product development
Research Sites
startups
revenue- driving agreements
What We Do
Virtici provides the leadership, space and funding support to transform innovations into products...
VALUE CREATION
-
1 Select
-
2 Innovate
-
3 Develop
Virtici leadership brings decades of experience
that intersect innovation and product development.
Virtici Ecosystem
Together we increase our reach and capital, resulting in enhanced innovation, cost-efficient product development, and more valuable medical products for patients.
Areas Of Innovation
Virtici is actively seeking the most innovative product and
platform concepts in the following disease areas.
-
Oncology
-
Microbiome
-
Neurology
-
Autoimmunity
-
Inflammation
-
Infectious Disease
The ASCEND Hub is a Regional Technology Accelerator Hub for the seven Western States: Alaska, Hawaii, Idaho, Montana, Nevada, New Mexico, and Wyoming. The NIH funded program empowers innovators to accelerate biomedical commercialization through entrepreneurial education, mentorship, and technology development funding.
Latest News
Precision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology’s Board of Directors
Javelin Oncology, Inc. announced today that the company has named Dennis H. Langer, M.D., J.D. to the company’s board of directors as an independent director. Dr. Langer has served as a director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies.
Read more
Celdara Medical Secures Funding to Develop an Adjuvanted Universal Flu Vaccine
Celdara Medical, LLC today announced that the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH) has awarded a two-year Small Business Innovation Research (SBIR) contract to fund the development of the novel, parasite-derived, antigen-sparing protein adjuvant ASP-1 for flu vaccines.
Read more
Javelin Oncology Hires Steven Yecies as Chief Executive Officer
Javelin Oncology announced today that the company has hired Steven Yecies as Chief Executive Officer. Yecies brings 30 years of experience as an accomplished senior executive, consultant, and investor in the healthcare and life sciences industry.
Read more
Scioto Biosciences Receives Series B Investment from Genome & Company
Scioto Biosciences announced today the closing of a strategic investment of up to $26.5M from Genome & Company and other investors to join in an upcoming tranche. Genome & Company is a leading microbiome company with headquarters in South Korea. The deal gives Genome & Co a majority stake in Scioto and expands its presence into the US.
Read more
Virtici ASCEND participant company, Inimmune, raises $22 Million in Series A Funding Led by Two Bear Capital
Inimmune, www.inimmune.com, a biotechnology company developing immune therapies and components for more effective vaccines, announced today that it raised $22 million in Series A funding.
Read more
Rise Therapeutics Secures Funding to Develop a Novel Immunologically-Directed Probiotic for the Treatment of Inflammatory Bowel Disease
Rise Therapeutics, LLC today announced that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) grant to fund the development of the novel engineered probiotic for the treatment of inflammatory bowel disease (IBD).
Read more